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Abstract
The prognostic improvement attributed to genetic markers over current prognostic system
has not been well studied for melanoma. The goal of this study is to evaluate the added
prognostic value of Vitamin D Pathway (VitD) SNPs to currently known clinical and demo-
graphic factors such as age, sex, Breslow thickness, mitosis and ulceration (CDF). We uti-
lized two large independent well-characterized melanoma studies: the Genes, Environment,
and Melanoma (GEM) and MD Anderson studies, and performed variable selection of VitD
pathway SNPs and CDF using Random Survival Forest (RSF) method in addition to Cox
proportional hazards models. The Harrell’s C-index was used to compare the performance
of model predictability. The population-based GEM study enrolled 3,578 incident cases of
cutaneous melanoma (CM), and the hospital-based MD Anderson study consisted of 1,804
CM patients. Including both VitD SNPs and CDF yielded C-index of 0.85, which provided
slight but not significant improvement by CDF alone (C-index = 0.83) in the GEM study. Sim-
ilar results were observed in the independent MD Anderson study (C-index = 0.84 and 0.83,
respectively). The Cox model identified no significant associations after adjusting for multi-
plicity. Our results do not support clinically significant prognostic improvements attributable
to VitD pathway SNPs over current prognostic system for melanoma survival.
Introduction
Cutaneous melanoma is a potentially fatal form of skin cancer. More than 10,000 individuals
in the US are expected to die from this disease in 2016 [1]. The American Joint Committee on
Cancer (AJCC) developed the I-IV staging system [2] for melanoma based on tumor charac-
teristics, including Breslow thickness, ulceration and mitoses, which is the major prognostic
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classification for melanoma. However, there is a broad range of survival rates among patients
of the same stage, and this variability suggests the need for developing new prognostic
markers.
Recent developments in genome technologies have provided promise and potential in uti-
lizing germline genetic alterations to develop improved classifications of melanoma leading to
more precise prognostication of disease. Current molecular melanoma research has mainly
focused on investigating the genetic association with the development and survival of mela-
noma to gain insights into melanoma etiology and progression, respectively. However, the
prognostic improvement attributed to genetic markers over existing clinical and demographic
factors has not been well studied. The single nucleotide polymorphisms (SNPs) in the VitD
pathway genes have been implicated in the development, progression and survival of mela-
noma [3, 4]. As well, an interaction effect between the BsmI (rs1544410) A allele in the VDR
gene and serum vitamin D levels on outcome has been reported, and this was despite the lack
of observed main effect of VDR genotypes on outcome [5]. Another study demonstrated an
association between vitamin D deficiency at time of diagnosis and thicker melanoma, a marker
of poorer prognosis [6].
The objective of this study is to evaluate whether incorporation of SNPs in the VitD path-
way would provide improved melanoma prognostic classification. Specifically, we investigated
whether coupling VitD pathway SNPs with known clinical and demographic information pro-
vides better prognostic effects than clinical/demographic factors alone for melanoma specific
survival, in an international population based genetic epidemiology of melanoma, the Genes,
Environment, and Melanoma (GEM) study. We used the genotype and phenotype data from
the MD Anderson study as an independent validation [7].
Materials and methods
The study design, sample and data collection methods for the GEM study were described else-
where [8]. In brief, the GEM Study is an international population-based study of melanoma
development and progression consisting of 3,578 incident cases of cutaneous melanoma,
where controls (n = 2,372) were newly diagnosed with invasive single primary melanomas and
the cases (n = 1,206) were newly diagnosed with multiple primary melanomas. The sample col-
lection, germline buccal DNA extraction, and genotyping pipeline along with standard quality
control procedures for the 38 VDR SNPs in GEM using the Sequenom MassARRAY iPLEX
platform, pyrosequencing and melting temperature assays were previously described [3, 9]. A
subset of SNPs were genotyped using a custom Illumina GoldenGate assay, where standard
quality control procedures were performed to ensure the quality of the Illumina SNP data. Spe-
cifically, we visually evaluated the genotype clustering images and excluded samples and SNPs
with genotyping call rates of<90%. There are 2993 samples genotyped using Illumina that
passed quality control. Assays were considered optimal according to degree of clustering of
repeats, the absence of signal in controls and reproducibility. Data on major clinical prognostic
factors for melanoma, demographic, sun exposure and histopathological variables were col-
lected for all study participants and were described previously [10]. Seventy SNPs from genes
in the VitD pathway, including 38 VDR SNPs and 32 additional SNPs genotyped by Sequenom
or Illumina platform, among 3,566 white subjects were included in the analyses. To illustrate
the genes evaluated in this study along with their biological roles, we have included a vitamin
D pathway diagram (S1 Fig) adapted from a previous report [11] which also incorporates the
anti-cancer effects of vitamin D [12, 13]. The list of SNPs along with their chromosome loca-
tions, minor/major alleles in the population, gene names, minor allele frequency (MAF) in
the GEM study participants, and genotyping platform are shown in S1 Table. These include
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functionally relevant SNPs or SNPs previously reported in other genetic association studies
that included the Vitamin D pathway genes [9, 11]. The linkage disequilibrium pattern for the
38 VDR SNPs was described elsewhere [9].
The MD Anderson study is a hospital-based study of cutaneous melanoma, consisting of
1804 melanoma patients presenting to clinics at MD Anderson [7]. A total of 1788 samples
among them were successfully genotyped and passed quality control using the Illumina
Human Omni1-Quad_v1-0_B array. The sample collection, DNA extraction methods, geno-
typing platform, and standard quality control procedures were described previously [7].
Genome-wide genotyping imputation was conducted using MACH [14] and the Hapmap2
CEU population reference panel [7]. Among the 70 VitD pathway SNPs genotyped in GEM,
65 were either genotyped or imputed in the MD Anderson study, and were evaluated as an
independent validation. The genotype data from the MD Anderson study [7] was obtained
from dbGap database (http://www.ncbi.nlm.nih.gov/gap) with accession number: phs000187.
v1.p1. The phenotype data and follow-up survival outcome from the MD Anderson study was
supplied by the study investigators.
The study protocol was approved by the Institutional Review Boards of all participating
institutions, including those at the British Columbia Cancer Agency, Vancouver, BC, CA;
Cancer Care Ontario, Toronto, ON, CA; Centro per la Prevenzione Oncologia, Torino, IT;
Memorial Sloan Kettering Cancer Center, New York, NY, US; Menzies Cancer Center,
Hobart, TAS, AU; University of California, Irvine, CA, US; University of Michigan, Ann
Arbor, MI, US; University of North Carolina, Chapel Hill, NC, US; University of Sydney, Syd-
ney, NSW, AU, and the University of Texas MD Anderson Cancer Center, Houston, TX, US.
Written informed consent was obtained from each participant.
Utilizing the genotype and phenotype data from the GEM study and the MD Anderson
study, we investigated the prognostic improvement of VitD pathway SNPs over the major
known prognostic factors including: age, sex, Breslow thickness, mitoses and ulceration. In the
GEM study we also performed a secondary analysis by including other additional prognostic
factors (histology, site, sun exposure, and phenotypic index) to evaluate the change in results
and model performance.
Summary statistics were used to describe the patient demographics and characteristics of
the common clinical and demographical factors in the two studies. Two-sided t-tests and
Wilcoxon rank-sum tests were used to compare continuous variables. Chi-squared tests were
performed to compare categorical variables. We applied the Random Survival Forest (RSF)
method [15] as well as Cox proportional hazards models to data from the two melanoma
studies. RSF is an ensemble tree method for analysis of right censored survival data [15]. Each
tree is built using a recursive portioning method to split the feature space, spanned by all pre-
dictor variables, into groups of subjects with similar association patterns between the predictor
variables and the survival outcome. Specifically, each tree is grown using a randomly drawn
bootstrap sample of the data. Based on a randomly selected subset of the variables, a survival
criterion involving survival time and censoring status information (log-rank test) is used to
split the tree nodes. Prediction is made by averaging over an ensemble of trees. Important
variables were selected based on two measures of the predictiveness of variables in a tree: 1)
variable importance (VIMP) [15], and 2) minimal depth of maximal subtree [16]. VIMP is a
measure of how important a variable is, which estimates the change in prediction error if that
variable is eliminated from analysis. Minimal depth assesses the predictiveness of variables
in a tree by estimating the minimal depth relative to the root node. A larger VIMP value or a
smaller minimal depth corresponds to better predictiveness of a variable.
For Cox proportional hazard regression models, Harrell’s C-index, an extension of the area
under the ROC curve (AUC), was calculated to measure the concordance probability between
No prognostic value added by vitamin D pathway SNPs for melanoma
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prognostic factors and survival outcome and thus compare the predictability of the selected
variables.
To further evaluate the prognostic effects of VitD SNPs on melanoma survival, we exam-
ined the relationship between VitD pathway SNPs and Breslow thickness as a marker of mela-
noma prognosis. Linear regression models were performed to assess the association between
SNPs and log transformed Breslow thicknesses. We also estimated the average causal media-
tion effect using a quasi-Bayesian Monte Carlo causal mediation analysis method [17, 18] to
investigate the impact of each SNP on Melanoma prognosis mediated by Breslow thickness.
Multiple comparisons were adjusted using Benjamini and Hochberg (BH) false discovery rate
procedure [19].
Results
The patient demographics and characteristics are displayed in Table 1. Compared to the sub-
jects in GEM, patients in the MD Anderson study were younger, had thicker tumors, more
ulceration, more mitoses, and more melanoma deaths. The gender distributions were similar
in the two studies. The differences between the two studies suggested more aggressive tumors
in the hospital-based MD Anderson study compared to the population-based GEM study.
The variables with positive VIMP values selected by the RSF method are described in
Table 2 in which major prognostic variables (age, sex, Breslow thickness, mitosis, and ulcera-
tion) are displayed in italic font and the “rs” (Reference Sequence) numbers denote VitD
Table 1. Patient demographics and characteristics of the GEM and MD Anderson studies.
Variable GEM Study (N = 3566) MD Anderson Study (N = 1788) P-Value
AgeMean ± SD (N) 58.2 ± 15.9 (N = 3566) 52.0 ± 14.5 (N = 1788) <.0001a
Median (min-max) 59.0 (7.0-97.0) 52.3 (14.9-94.1)
Log Breslow
Mean ± SD (N) -0.1 ± 0.8 (N = 3480) 0.2 ± 0.9 (N = 1536) <.0001a
Median (min-max) -0.3 (-3.2 to 3.4) 0.1 (-2.3 to 3.6)
Follow up in months Mean ± SD (N) 83.6 ± 18.7 (N = 3566) 91.1 ± 58.7 (N = 1786) 0.025b
Median (min-max) 91.0 (4.8-127.0) 82.2 (1.6-625.9)
Melanoma Specific Death
No 3312 (92.9%) 1472 (82.3%) <.0001c
Yes 254 (7.1%) 316 (17.7%)
Sex
M 2004 (56.2%) 1050 (58.7%) 0.078c
F 1562 (43.8%) 738 (41.3%)
Ulceration
Missing 829 (23.2%) 371 (20.7%) <.0001c
Absent 2475 (69.4%) 1158 (64.8%)
Present 262 (7.3%) 259 (14.5%)
Mitoses
missing 819 (23.0%) 438 (24.5%) <.0001c
Absent 1520 (42.6%) 415 (23.2%)
Present 1227 (34.4%) 935 (52.3%)
a P value was based on the pooled variances t-test.
b P value was based on the Wilcoxon rank-sum test.
c P value was based on the Chi-square test.
https://doi.org/10.1371/journal.pone.0174234.t001
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pathway SNPs. In both the GEM study and MD Anderson study, existing clinical and demo-
graphic prognostic factors had larger VIMP values, indicating higher predictability for mela-
noma survival compared to SNPs. Table 3 gives results of the secondary analyses of including
additional prognostic variables (histology, site, sun exposure, and phenotypic index) in the
RSF model in the GEM study. We again observed higher prognostic effects of the clinical and
demographical factors than the SNPs on melanoma specific survival.
In the GEM study, including both VitD SNPs and major known prognostic factors selected
by the RSF method in a Cox regression model yields a C-index (a concordance measure) of
0.85, which provided slight but not significant improvement by using the known prognostic
factors alone (age, sex, Breslow thickness, mitoses and ulceration) alone (C-index = 0.83). Sim-
ilar results were observed in the MD Anderson study; the C-index is 0.85 for combined SNPs
and clinical factors, and 0.84 for clinical factors (age, sex, Breslow thickness, mitoses and ulcer-
ation) alone. When additional prognostic factors (i.e. histology, site, sun exposure, and
Table 2. The major clinical and demographical prognostic variables and genetic variants selected by Random Survival Forest (RSF) ordered
based on the variable importance (VIMP) prediction measure.
GEM Study MD Anderson Study
Variable VIMPa Variable VIMP
logBreslow 0.047 logBreslow 0.053
Mitoses 0.0074 Ulceration 0.016
Ulceration 0.0069 Mitoses 0.0053
Age 0.0045 Age 0.0028
Sex 0.0012 rs7594289 (CYP27A1) 0.0018
rs12512631 (GC) b 0.00060 Sex 0.0014
rs3787555 (CYP2R1) 0.00052 rs7861779 (RXRA) 0.00054
rs2239182 (VDR) 0.00052 rs3782905 (VDR) 0.00049
rs7041 (GC) 0.00037 rs4646536 (CYP27B1) 0.00034
rs10875712 (VDR) 0.00036 rs7974708 (VDR) 0.00028
rs1051130 (CCND3) 0.00033 rs886441 (VDR) 0.00027
rs2228570 (VDR) 0.00030 rs7299460 (VDR) 0.00026
rs2189480 (VDR) 0.00029 rs4809959 (CYP2R1) 0.00021
rs4760648 (VDR) 0.00025 rs11568820 (VDR) 0.00019
rs7305032 (VDR) 0.00022 rs11168275 (VDR) 0.00016
rs2107301 (VDR) 0.00019 rs11168287 (VDR) 0.00015
rs222040 (GC) 0.00019 rs2228570 (VDR) 0.00015
rs3218089 (CCND3) 0.00017 rs2282679 (GC) 0.00014
rs1989969 (VDR) 0.00017 rs10875712 (VDR) 0.00013
rs7299460 (VDR) 0.00013 rs1051130 (CCND3) 0.00012
rs927650 (CYP2R1) 0.00011 rs2296241 (CYP2R1) 0.00010
rs2544027 (VDR) 0.000042 rs2189480 (VDR) 0.000099
rs10776909 (RXRA) 0.000039 rs7041 (GC) 0.000079
rs1544410 (VDR) 0.000034 rs4760648 (VDR) 0.000076
rs2238140 (VDR) 0.000033 rs4809960 (CYP2R1) 0.000066
rs4760674 (VDR) 0.000026 rs2107301 (VDR) 0.000048
rs7974708 (VDR) 0.000026 rs1790349 (DHCR7) 0.000047
rs11574139 (VDR) 0.000023 rs4760674 (VDR) 0.000032
a Larger VIMP value corresponds to better predictiveness of a variable (see materials and methods section for more details). The clinical, demographical
variables and genetic variants selected are ordered based on the VIMP measure.
b SNP gene names are shown in parentheses.
https://doi.org/10.1371/journal.pone.0174234.t002
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phenotypic index) were included in the analysis of GEM study, we did not observe significant
prognostic improvements of incorporating the VitD SNPs (C index = 0.84) over using clinical
and demographic factors (age, Breslow thickness, mitoses, ulceration, histology, site, sunburn,
status, phenotypic index, freckle, education) alone (C index = 0.83). RSF analyses using mini-
mal depth as the measure of predictiveness yielded similar results (data not shown).
Using the Cox proportional hazards model, we identified nine SNPs nominally significantly
associated with melanoma survival in the GEM study (P<0.05), and nine such SNPs in the
MD Anderson study (Table 4). Among them the commonly studied rs1544410 (BsmI) and
rs731236 (TaqI) polymorphisms were significant in both studies, suggesting their potential
biological role in melanoma survival. However, after correcting for multiple tests, none of the
SNPs reached the FDR cutoff of 0.05. Similar results were observed in the analyses of Breslow
thickness as a marker for melanoma prognosis in both GEM and MD Anderson study. No
Table 3. The clinical, demographical variables and genetic variants selected by Random Survival Forest (RSF) ordered based on the variable
importance (VIMP) prediction measure in the secondary analysis of GEM study by including additional prognostic factors.
GEM Study MD Anderson Study
Variable VIMPa Variable VIMP
logbreslow 0.049 logbreslow 0.053
Histology 0.0054 Ulceration 0.016
Ulceration 0.0046 Mitoses 0.0053
Age 0.0030 Age 0.0028
Mitoses 0.0025 rs7594289 (CYP27A1) 0.0018
Site 0.0022 Sex 0.0014
rs12512631 (GC) b 0.00094 rs7861779 (RXRA) 0.00054
rs7041 0.00075 rs3782905 (VDR) 0.00049
Burns 0.00049 rs4646536 (CYP27B1) 0.00034
Status c 0.00041 rs7974708 (VDR) 0.00028
rs1051130 (CCND3) 0.00038 rs886441 (VDR) 0.00027
Phenotypic_index 0.00031 rs7299460 (VDR) 0.00026
rs2107301 (VDR) 0.00029 rs4809959 (CYP2R1) 0.00021
Freckle 0.00023 rs11568820 (VDR) 0.00019
rs2189480 (VDR) 0.00021 rs11168275 (VDR) 0.00016
rs2228570 (VDR) 0.00020 rs11168287 (VDR) 0.00015
Education 0.00019 rs2228570 (VDR) 0.00015
rs3787555 (CYP2R1) 0.00014 rs2282679 (GC) 0.00014
rs10776909 (RXRA) 0.00012 rs10875712 (VDR) 0.00013
rs7974708 (VDR) 0.00012 rs1051130 (CCND3) 0.00012
rs10875712 (VDR) 0.000094 rs2296241 (CYP2R1) 0.00010
rs2239182 (VDR) 0.000073 rs2189480 (VDR) 0.000099
rs7861779 (RXRA) 0.000072 rs7041 (GC) 0.000079
rs4760648 (VDR) 0.000069 rs4760648 (VDR) 0.000076
rs927650 (CYP2R1) 0.0000078 rs4809960 (CYP2R1) 0.000066
rs11168275 (VDR) 0.0000035 rs2107301 (VDR) 0.000048
rs1790349 (DHCR7) 0.000047
rs4760674 (VDR) 0.000032
a Larger VIMP value corresponds to better predictiveness of a variable (see materials and methods section for more details). The clinical, demographical
variables and genetic variants selected are ordered based on the VIMP measure.
b SNP gene names are shown in parentheses.
c Status refers to patients diagnosed with single or multiple primary melanomas.
https://doi.org/10.1371/journal.pone.0174234.t003
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Table 4. The association between SNPs and melanoma specific survival identified by Cox proportional hazard regression model in the GEM study
and MD Anderson study before and after the FDR correction.
GEM study MDACC Study
SNP genename N obs HR (95% CI)a Raw P-value FDR N obs HR (95% CI)b Raw P-value FDR type
rs1544410 VDR 3401 0.78 (0.65 -0.95) 0.011 0.22 1528 0.77 (0.64 -0.94) 0.008 0.25 genotyped
rs2239182 VDR 3372 1.25 (1.05 -1.48) 0.012 0.22 1536 1.17 (0.97 -1.40) 0.10 0.45 genotyped
rs7305032 VDR 3250 1.23 (1.02 -1.48) 0.031 0.31 1536 0.86 (0.72 -1.04) 0.12 0.45 imputed
rs731236 VDR 3406 0.82 (0.68 -0.98) 0.031 0.31 1536 0.82 (0.68 -1.00) 0.046 0.35 genotyped
rs4760674 VDR 3439 1.21 (1.01 -1.44) 0.038 0.33 1536 1.07 (0.89 -1.29) 0.48 0.79 genotyped
rs2189480 VDR 3414 1.19 (1.00 -1.43) 0.053 0.37 1536 0.95 (0.78 -1.14) 0.56 0.79 genotyped
rs3782905 VDR 3445 0.84 (0.69 -1.02) 0.083 0.40 1536 0.91 (0.73 -1.14) 0.42 0.79 imputed
rs2238140 VDR 3443 1.17 (0.98 -1.39) 0.09 0.40 1536 0.86 (0.71 -1.04) 0.12 0.45 imputed
rs12370156 VDR 3434 1.16 (0.97 -1.38) 0.10 0.40 1536 0.87 (0.72 -1.04) 0.13 0.45 imputed
rs2071358 VDR 3427 0.81 (0.63 -1.04) 0.10 0.40 1536 1.07 (0.84 -1.36) 0.60 0.79 genotyped
rs11168284 VDR 3414 0.85 (0.70 -1.04) 0.11 0.40 1536 1.15 (0.95 -1.39) 0.16 0.49 imputed
rs7299460 VDR 3415 0.86 (0.71 -1.04) 0.12 0.40 1536 1.02 (0.84 -1.25) 0.81 0.93 imputed
rs1989969 VDR 3454 1.15 (0.96 -1.38) 0.13 0.40 1536 1.00 (0.83 -1.21) 0.99 0.99 imputed
rs7139166 VDR 3376 1.15 (0.96 -1.38) 0.13 0.40 1536 1.04 (0.87 -1.26) 0.65 0.82 imputed
rs4516035 VDR 3428 1.15 (0.96 -1.37) 0.13 0.40 1536 1.04 (0.87 -1.26) 0.65 0.82 genotyped
rs7974708 VDR 3441 0.87 (0.72 -1.05) 0.14 0.42 1536 0.92 (0.73 -1.17) 0.50 0.79 imputed
rs11168314 VDR 3422 0.84 (0.67 -1.06) 0.15 0.42 1536 1.07 (0.84 -1.35) 0.59 0.79 imputed
rs11574139 VDR 3445 0.68 (0.39 -1.19) 0.18 0.47 1536 1.15 (0.70 -1.91) 0.58 0.79 imputed
rs1015390 VDR 3440 0.83 (0.63 -1.09) 0.18 0.47 1536 0.97 (0.75 -1.26) 0.84 0.93 imputed
rs4073729 VDR 3437 0.84 (0.64 -1.10) 0.20 0.50 1536 0.96 (0.74 -1.25) 0.75 0.92 imputed
rs7965281 VDR 3261 1.13 (0.93 -1.38) 0.21 0.50 1536 0.90 (0.75 -1.07) 0.22 0.56 imputed
rs10459217 VDR 3427 0.87 (0.69 -1.09) 0.22 0.50 1536 0.98 (0.78 -1.25) 0.89 0.93 imputed
rs10875712 VDR 3413 1.11 (0.93 -1.33) 0.26 0.54 1536 0.89 (0.74 -1.08) 0.25 0.58 imputed
rs2544027 VDR 3447 0.92 (0.77 -1.09) 0.31 0.61 1536 0.94 (0.78 -1.13) 0.51 0.79 imputed
rs11568820 VDR 3075 0.89 (0.70 -1.14) 0.35 0.66 1536 1.03 (0.82 -1.29) 0.80 0.93 imputed
rs2107301 VDR 3440 1.09 (0.90 -1.32) 0.38 0.70 1531 1.00 (0.81 -1.22) 0.96 0.98 genotyped
rs2544038 VDR 3418 0.93 (0.78 -1.10) 0.40 0.70 1536 0.94 (0.78 -1.13) 0.52 0.79 imputed
rs4760648 VDR 3429 0.93 (0.77 -1.12) 0.44 0.74 1536 1.18 (0.98 -1.42) 0.079 0.45 genotyped
rs6823 VDR 3426 1.07 (0.90 -1.27) 0.47 0.77 1536 0.93 (0.77 -1.12) 0.44 0.79 imputed
rs2544028 VDR 3428 0.94 (0.79 -1.12) 0.50 0.78 1536 0.93 (0.77 -1.13) 0.48 0.79 imputed
rs11168275 VDR 3463 0.93 (0.75 -1.15) 0.50 0.78 1536 1.06 (0.86 -1.30) 0.58 0.79 genotyped
rs2254210 VDR 2810 1.06 (0.87 -1.31) 0.55 0.82 1536 0.83 (0.68 -1.01) 0.064 0.42 genotyped
rs886441 VDR 3427 1.07 (0.85 -1.33) 0.58 0.84 1536 1.19 (0.96 -1.48) 0.12 0.45 genotyped
rs4237856 VDR 3402 1.04 (0.86 -1.27) 0.67 0.92 1536 1.10 (0.89 -1.36) 0.39 0.77 imputed
rs2228570 VDR 3305 0.97 (0.79 -1.18) 0.74 0.93 1536 0.82 (0.69 -0.99) 0.036 0.35 imputed
rs2238135 VDR 3446 0.97 (0.79 -1.19) 0.75 0.93 1530 0.87 (0.70 -1.08) 0.21 0.55 genotyped
rs10875694 VDR 3465 0.97 (0.77 -1.23) 0.80 0.93 1536 0.76 (0.59 -0.98) 0.032 0.35 imputed
rs2239181 VDR 3437 1.03 (0.76 -1.39) 0.87 0.94 1536 1.20 (0.89 -1.63) 0.24 0.58 genotyped
rs11574143 VDR 2780 1.02 (0.73 -1.42) 0.91 0.95 1533 1.25 (0.92 -1.70) 0.15 0.49 genotyped
rs11168287 VDR 3411 1.00 (0.83 -1.19) 0.97 0.97 1536 0.88 (0.74 -1.05) 0.17 0.49 genotyped
rs34421776 TCEAL1 2733 2.00 (1.16 -3.47) 0.013 0.22 N/Ac
rs10776909 RXRA 2724 0.80 (0.63 -1.01) 0.06 0.39 1535 0.93 (0.75 -1.16) 0.52 0.79 genotyped
rs7861779 RXRA 2766 1.27 (0.97 -1.65) 0.08 0.40 1536 1.29 (1.00 -1.65) 0.049 0.35 imputed
rs3118538 RXRA 2829 1.80 (0.57 -5.70) 0.32 0.61 N/A
rs1151 PPP1R14 2681 1.07 (0.83 -1.37) 0.62 0.87 1536 1.02 (0.80 -1.30) 0.87 0.93 genotyped
(Continued )
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significant association between SNPs and Breslow thickness were identified after correcting
for multiple tests. The average causal mediation effects measuring the SNP impact on mela-
noma survival mediated through Breslow thickness yielded no significant results.
Discussion
Utilizing the population-based GEM study, we did not observe an enhanced prognostic classi-
fication for melanoma by incorporating VitD pathway SNPs into the known major prognostic
measures (i.e. age, sex, Breslow thickness, mitoses and ulceration). Using the MD Anderson
study as an independent validation, we observed similar results that Breslow thickness, ulcera-
tion, mitoses and age are consistently selected as the top prognostic variables. When additional
prognostic factors (i.e. histology, site, sun exposure, and phenotypic index) were included in
the analysis of the GEM study, the tumor factors (histology and site) were again selected as var-
iables with higher prognostic effects compared to VitD pathway SNPs.
Table 4. (Continued)
GEM study MDACC Study
SNP genename N obs HR (95% CI)a Raw P-value FDR N obs HR (95% CI)b Raw P-value FDR type
rs3829251 NADSYN1 2791 1.04 (0.76 -1.43) 0.81 0.93 1536 1.34 (1.06 -1.69) 0.016 0.25 genotyped
rs7041 GC 2785 0.77 (0.63 -0.94) 0.012 0.22 1536 1.13 (0.94 -1.35) 0.19 0.54 genotyped
rs222040 GC 3382 0.80 (0.67 -0.96) 0.016 0.22 1536 0.91 (0.76 -1.09) 0.30 0.65 imputed
rs12512631 GC 2788 1.19 (0.96 -1.48) 0.10 0.40 1536 0.85 (0.70 -1.03) 0.098 0.45 genotyped
rs2282679 GC 2794 0.97 (0.77 -1.23) 0.81 0.93 1536 1.02 (0.84 -1.24) 0.86 0.93 genotyped
rs1790349 DHCR7 2811 1.04 (0.77 -1.40) 0.79 0.93 1536 1.37 (1.08 -1.73) 0.009 0.25 genotyped
rs3787555 CYP2R1 2788 1.25 (1.01 -1.56) 0.042 0.33 1535 0.94 (0.75 -1.18) 0.59 0.79 genotyped
rs4809960 CYP2R1 2731 1.15 (0.91 -1.45) 0.25 0.54 1536 0.84 (0.68 -1.04) 0.10 0.45 genotyped
rs2244719 CYP2R1 2715 1.17 (0.88 -1.57) 0.29 0.59 N/A
rs2762939 CYP2R1 2759 1.11 (0.86 -1.45) 0.42 0.71 1536 1.11 (0.89 -1.38) 0.38 0.77 imputed
rs2296241 CYP2R1 2784 0.94 (0.76 -1.16) 0.55 0.82 1536 1.15 (0.96 -1.39) 0.13 0.45 genotyped
rs927650 CYP2R1 2770 1.06 (0.86 -1.30) 0.60 0.86 1536 1.06 (0.88 -1.27) 0.52 0.79 genotyped
rs2181874 CYP2R1 2792 1.04 (0.83 -1.32) 0.73 0.93 1536 1.07 (0.86 -1.33) 0.55 0.79 genotyped
rs4809959 CYP2R1 2756 0.97 (0.79 -1.20) 0.79 0.93 1536 1.21 (1.01 -1.45) 0.043 0.35 genotyped
rs2060793 CYP2R1 2788 0.98 (0.80 -1.21) 0.88 0.94 1536 1.02 (0.85 -1.23) 0.84 0.93 genotyped
rs2762941 CYP2R1 2802 0.99 (0.80 -1.22) 0.90 0.95 1534 1.13 (0.93 -1.38) 0.22 0.56 genotyped
rs6022999 CYP2R1 2811 1.01 (0.79 -1.29) 0.92 0.95 1536 0.89 (0.71 -1.11) 0.29 0.64 genotyped
rs4646536 CYP27B1 2799 1.02 (0.82 -1.27) 0.83 0.94 1536 0.91 (0.75 -1.11) 0.36 0.76 imputed
rs7594289 CYP27A1 2747 0.97 (0.79 -1.18) 0.72 0.93 1536 1.26 (1.05 -1.52) 0.012 0.25 imputed
rs35456792 CDKN1B 2819 0.00 (0.00- >999) 0.97 0.97 N/A
rs1801270 CDKN1A 2789 1.14 (0.84 -1.54) 0.39 0.70 1536 1.03 (0.71 -1.50) 0.88 0.93 imputed
rs1059234 CDKN1A 3426 1.06 (0.75 -1.50) 0.76 0.93 1536 1.03 (0.71 -1.50) 0.88 0.93 imputed
rs3218089 CCND3 2762 0.65 (0.38 -1.10) 0.11 0.40 N/A
rs1051130 CCND3 2781 0.98 (0.79 -1.22) 0.86 0.94 1536 1.04 (0.86 -1.25) 0.71 0.89 imputed
rs6599638 C10orf88 2754 1.14 (0.93 -1.41) 0.22 0.50 1536 1.00 (0.83 -1.19) 0.97 0.98 genotyped
a GEM study: model adjusted for age, sex, center, status, time-dependent crossover status, and log transformed Breslow thickness; HR (95% CI): per minor
allele hazard ratio (95% confidence interval).
b MD Anderson study: model adjusted for age, sex, and log transformed Breslow thickness; HR (95% CI): per minor allele hazard ratio (95% confidence
interval).
c The SNP was not genotyped/imputed in the MD Anderson study.
https://doi.org/10.1371/journal.pone.0174234.t004
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Findings using a sophisticated random survival forest (RSF) approach and Cox propor-
tional hazards model and application to two independent melanoma studies yield similar
results. While both RSF and Cox models aim to identify variables that best predict the survival
outcome, the mechanisms implemented in the two algorithms are different. The Cox regres-
sion model is the widely used method for investigating the relationship between covariates of
interest and survival outcome, which estimates the log-linear relationship between covariates
and the underlying hazard function and provides clinically interpretable results. The RSF
method is a nonparametric machine learning method which assesses the prediction accuracy
of ensemble trees, and introduced two randomnesses where a randomly drawn bootstrap
sample was used to grow a tree and at each split a randomly selected subset of variables was
selected as candidates [15, 20]. The RSF method was demonstrated to outperform the Cox
model when possible non-linear relationships exist [21]. Due to the aforementioned different
mechanisms used in the two methods, we observed that SNPs with the highest VIMP values
may not necessarily be those identified in Cox regression model. However, the overall conclu-
sion that VitD pathway SNPs do not provide significant prognostic improvement for mela-
noma over current prognostic system is consistent in both analyses.
Although the two independent studies have different designs, population-based vs. hospi-
tal-based, and thus have distinct patient characteristics, we consistently observed higher
prognostic effects for the clinical factors known to be associated with melanoma outcome
compared to the SNPs in predicting melanoma specific survival. This lack of predictability
suggests the limited potential use of adding VitD pathway SNPs to the prognostic system for
melanoma. Studies investigating the improvement of including genetic factors in predicting
melanoma risk have reported effects with a variety of magnitude. It was reported that the
improvement of melanoma risk prediction by adding MC1R to age, sex, and cutaneous mela-
nin phenotypes is modest and too small to be valuable in clinical setting [22]. Other studies
have reported statistically significant, but small [23] to modest [24] improvement in prediction
of melanoma risk by adding MC1R genotype to traditional demographic and pigmentation
characteristics.
It is important to note from our power analysis that the GEM study has a sufficiently large
sample size to detect increase in AUC. In the GEM study sample, we have 92% power to detect
an increase of 0.04 between a diagnostic test with an AUC of 0.80 and another diagnostic test
with an AUC of 0.84 using a one-sided z-test at a significance level of 0.05. The modest
improvement in prognostic effects by including the VitD pathway SNPs is not likely due to the
sample size issue.
The large-scale genotyping technologies and genetic epidemiology studies of melanoma
provide promise for unraveling patients’ genetic makeup and developing genetic prognostic
markers for melanoma progression. The VitD pathway SNPs were reported in previous publi-
cations to be significantly associated with melanoma specific survival [3, 4], suggesting its key
important role in understanding the biological mechanisms for melanoma progression. To
date there are limited evidence for SNPs that significantly predict melanoma survival, and the
reported effect sizes of SNP predictability in survival are typically small [25, 26]. The findings
from this study yielded similar results. We did not find an improvement in melanoma progno-
sis beyond that attributed to known prognostic variables by including VitD pathway SNPs.
The genetic variations contributing to melanoma survival and progression are likely to be
multi-dimensional, and may involve complicated biological pathway functionality and gene
environment interactions in addition to single SNPs and warrants further investigation.
Besides the strengths of this study, we have noted some limitations. The major limitation of
our study is that instead of a genome-wide association study investigating all human genes, we
have conducted a confirmatory study which focused on a subset of SNPs in the vitamin D
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Pathway that were previously reported to be associated with melanoma or biologically func-
tionally relevant. Second, other than the classical vitamin D pathway, we have not investigated
the recently reported novel alternative pathways of vitamin D activation which may have com-
plicated the findings. Different from classical vitamin D activation, novel pathways of vitamin
D3 and 7-dehydrocholesterol initiated by CYP11A1were recently reported [27], which were
demonstrated to be of significant physiological role [28]. Novel vitamin D3 hydroxyderivatives
resulting from CYP11A1 action were detectable in human epidermis and serum and in pig
adrenal glands [29]. It was demonstrated that the endogenously produced novel D3 hydroxy-
derivatives can act as biased agonists of VDR and inverse agonists of the retinoic acid-related
orphan receptors (RORα and RORγ) [30, 31]. It was also shown that RORα and RORγ are
expressed in normal and pathological human skin [30], and that decreased expression of
RORα and RORγ is associated with the development and progression of melanoma [32].
Third, we had limited ability to explore some factors previously demonstrated to contribute to
melanoma prognosis. The reduced expression of vitamin D receptor (VDR) was reported to be
related to shorter overall survival [33]. Low expression of the Vitamin D activating enzyme 1α-
Hydroxylase (CYP27B1) were found to be associated with shorter overall survival and disease
free survival in melanomas[34]. Fourth, we acknowledge the limitation that we have not col-
lected data on patients’ actual vitamin D status such as blood level of 25-hydroxyvitamin D
and 1, 25-dihydroxyvitamin D. It would be important to evaluate the role of actual vitamin D
status on melanoma prognosis that potentially confounds the SNP effects, which may provide
more information and shed light on clinical decision making, such as vitamin D supplement
for melanoma patients based on their genetic background.
Future larger genome-wide or sequencing studies exploring the melanoma prognostic
effects more comprehensively by including SNPs from alternative pathways of vitamin D acti-
vation as well as other biological pathways are suggested. Evaluation of the association between
actual vitamin D status and melanoma survival that are independent of SNPs would also con-
tribute to our understanding of the melanoma prognosis. Finally, in terms of the biology we
may find more meaningful results when accounting for sun exposure, and therefore our future
work will include investigating the prognostic effects of gene-environment interactions. We
will also explore combining the prognostic effects of SNPs into that of biologically meaningful
genes or pathways, and evaluate the improvement of melanoma prognosis by adding genes or
pathways in the future.
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